TY  - GEN
AU  - Delord,Jean-Pierre
AU  - Robert,Caroline
AU  - Nyakas,Marta
AU  - McArthur,Grant A
AU  - Kudchakar,Ragini
AU  - Mahipal,Amit
AU  - Yamada,Yasuhide
AU  - Sullivan,Ryan
AU  - Arance,Ana
AU  - Kefford,Richard F
AU  - Carlino,Matteo S
AU  - Hidalgo,Manuel
AU  - Gomez-Roca,Carlos
AU  - Michel,Daniela
AU  - Seroutou,Abdelkader
AU  - Aslanis,Vassilios
AU  - Caponigro,Giordano
AU  - Stuart,Darrin D
AU  - Moutouh-de Parseval,Laure
AU  - Demuth,Tim
AU  - Dummer,Reinhard
TI  - Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic 
SN  - 1557-3265
PY  - 2018///0511
KW  - Animals
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Carbamates
KW  - Disease Models, Animal
KW  - Drug Evaluation, Preclinical
KW  - Drug Monitoring
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Melanoma
KW  - drug therapy
KW  - Mice
KW  - Molecular Targeted Therapy
KW  - Mutation
KW  - Neoplasm Staging
KW  - Protein Kinase Inhibitors
KW  - Proto-Oncogene Proteins B-raf
KW  - antagonists & inhibitors
KW  - Sulfonamides
KW  - Treatment Outcome
KW  - Xenograft Model Antitumor Assays
N1  - Publication Type: Clinical Trial, Phase I; Journal Article
UR  - https://doi.org/10.1158/1078-0432.CCR-16-2923
ER  -